Abstract. Psoriasis is a chronic inflammatory skin disease condition that involves altered expression of a broad spectrum of proinflammatory cytokines which are associated with activation of T cells and proliferation of keratinocytes. Currently approved biological products for psoriasis treatment fall into two main classes: cytokine modulators and biologics targeting T cells. In psoriatic patients, elevated levels of proinflammatory cytokines are observed. Elevated proinflammatory cytokines can suppress some cytochrome P450 (CYP) enzymes, and the treatment of psoriasis with biological products can reduce proinflammatory cytokine levels. Therefore, the exposure of CYP substrate drugs is anticipated to be affected by the psoriasis disease resulting in a higher exposure than in healthy state (named disease-drug interaction) as well as by the biological treatments due to disease improvements resulting in a decrease in exposure (named disease-drug-drug interaction, disease-DDI). However, the quantitative impact on CYP substrate exposure due to disease or due to treatment with biological products remains to be evaluated. The objective of the current review is to provide an overview of the therapeutic targets and cytokinerelated pharmacodynamic effects of biological products in psoriasis treatment with a particular focus on their implications for disease-DDI. The clinical study design considerations for psoriasis disease-DDI evaluation are also discussed.
INTRODUCTION
Psoriasis represents a chronic skin disease affecting approximately 2-3% population globally and is characterized by recurrent episodes of erythematosus skin plaques with irregular borders and silvery scales (1) (2) (3) . Conventional therapies for psoriasis have not been fully satisfactory (4) . Biological products have been shown to be highly effective and represent important treatment options for psoriasis (5, 6) . Currently approved biological therapies are indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidate for phototherapy or systemic therapy. Approved dosing regimens of biologics for psoriasis treatment often include one for induction treatment and one for maintenance treatment because of the chronic nature of the disease. The induction dose regimen may contain higher starting doses and/or more frequent dosing to achieve the desired steady state concentrations quickly for a potential rapid onset of response. The purpose of maintenance treatment is to maintain response in responders and a lower and/or less frequent dosing regimen may be sufficient. Table I summarizes the pharmacokinetic (PK) properties and dosing regimens for the four anti-cytokine products (etanercept, infliximab, adalimumab, and ustekinumab) approved for psoriasis treatment. Psoriasis is increasingly a first-choice disease condition for proof-of-principle clinical trials in the development of new biological products for chronic inflammatory diseases, as is the case for ustekinumab.
With both environmental and genetic factors contributing to its pathogenesis, psoriasis is considered as a systemic inflammatory disease associated with activation of T cells, secretion of proinflammatory cytokines, and proliferation of keratinocytes (7, 8) . The inflammatory process of psoriasis involves altered expression of a broad spectrum of proinflammatory and anti-inflammatory cytokines, and elevated levels of proinflammatory cytokines are observed in psoriatic patients (9) (10) (11) (12) (13) (14) (15) . Proinflammatory cytokines have been shown to modify the formation, stability, and activity of cytochrome P450 (CYP) enzymes and, therefore, have the potential to alter the systemic exposure of concomitantly administered
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drugs that are substrates for CYP enzymes, leading to the occurrence of disease-drug interactions (16) (17) (18) . In turn, the biological products for psoriasis treatment could modulate the proinflammatory cytokine levels and influence the expression of specific CYP enzymes as well as the exposure of CYP enzyme substrates, which is considered psoriasis disease-drug-drug interactions (disease-DDI). The consequence of the disease-DDI would be a loss of efficacy of the CYP substrate drugs.
In this review, we aim to (a) provide an overview of the therapeutic targets, the mechanisms of action, and the cytokine-related pharmacodynamic effects of biological products used for psoriasis treatment in Part 1, (b) discuss the implications for psoriasis disease-DDI in Part 2, (c) present study design considerations for psoriasis disease-DDI clinical evaluation in Part 3, and (d) provide our perspectives and conclusions in Part 4.
PART 1: THERAPEUTIC TARGETS AND PHARMACODYNAMICS
Based on the mechanisms of action, the biological products for psoriasis treatment can be categorized into two main classes: cytokine modulators (anti-cytokines) and biologics targeting T cells (Table II) (19) (20) (21) (22) (23) (24) (25) (26) . Four anticytokines have been approved in the USA for the treatment of psoriasis: infliximab, adalimumab, etanercept, and ustekinumab. The approved biologics targeting T cells include efalizumab and alefacept, however, both have been voluntarily withdrawn from the market in the USA (9, 27) . Focusing on these approved biological products with clinically validated therapeutic targets, we provide an overview of their mechanisms of action and the related pharmacodynamic characteristics. Readers are also referred to other publications for even broader discussions of the emerging new therapeutic targets and biomarkers in psoriasis research which may foster future personalized therapies for psoriasis treatment (28) (29) (30) (31) (32) (33) .
Anti-cytokines Targeting TNFα
Three of four approved anti-cytokines are targeting tumor necrosis factor α (TNFα): infliximab, adalimumab, and etanercept. Infliximab and adalimumab are monoclonal antibodies with binding specificity to TNFα, whereas etanercept is a fusion protein and binds to both TNFα and TNFβ. All three anti-cytokines block the interaction of TNFα with its receptors. Other notable TNFα inhibitors, e.g., certolizumab pegol and golimumab, have been approved for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases, and they have ongoing clinical investigations in subjects with psoriasis (34) (35) (36) (37) .
Anti-TNFα treatment has been generally found to reduce the epidermal thickness and infiltration of inflammatory cells in histological studies. TNFα is a naturally occurring proinflammatory cytokine involved in immune responses (38) , and elevated levels of TNFα were found in psoriasis plaques and serum (39, 40) . Serum TNFα level was shown to be correlated with disease severity and the effectiveness of treatment in a clinical trial with 30 psoriatic subjects (40) . TNFα levels in lesional psoriatic skin were reported in a small study to be reduced in psoriatic subjects received adalimumab treatment (41) . Additionally, anti-TNFα treatment was reported to affect other cytokine levels; for example, effective treatment of psoriasis with etanercept was associated with reduced serum levels of IL-17 and IL-22 (42) , suggesting the interconnectivity of the cytokine network in inflammatory conditions.
Anti-cytokines Targeting IL-12/Th1 and IL-23/Th17
Ustekinumab is unique among the currently approved anti-cytokine biologics because psoriasis is its first approved indication. Ustekinumab targets the p40 protein subunit used by both interleukins (IL)-12 and IL-23, and inhibits both IL-12/Th1 and IL-23/Th17 pathways (43, 44) . Briakinumab, another IL-12/23p40 antagonist, was in development for psoriasis treatment, but its biological license application was withdrawn (5, 45) . Several emerging anti-cytokines are being developed for more selective inhibition of the IL-23/Th17 pathway (46) , which include biologics with binding specificity to IL-23p19, e.g., CNTO 1959 and SCH 900222 (5, 6, 47) , and biologics targeting IL-17 or IL-17 receptors, e.g., brodalumab, ixekizumab, and secukinumab (5, (48) (49) (50) (51) (52) .
IL-12 and IL-23 are naturally occurring proinflammatory cytokines involved in immune responses (53) (54) (55) . Prior to the discovery of the IL-23/Th17 pathway, psoriasis was only (57, 58) . As reported in the product labeling, in a small exploratory study, ustekinumab decreased the expression of mRNA of IL-12 and IL-23 in lesional skin biopsies measured at baseline and up to 2 weeks posttreatment in subjects with psoriasis.
Biologics Targeting T Cells
Although not currently available on the US market due to voluntary withdrawal by the manufacturers, two anti-T cells biologics have been approved for the treatment of psoriasis: efalizumab and alefacept. Efalizumab binds to CD11a, α subunit of leukocyte-function-associated antigen type 1 (LFA-1). Alefacept is a LFA-3/Fc fusion protein targeting CD2. While only approved for the indications of RA and juvenile idiopathic arthritis, abatacept is another anti-T cells biological product, a fusion protein consisting of the extracellular domain of human cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4) linked to a modified Fc.
Psoriasis is characterized by chronic inflammation mediated by T cell activation, differentiation, and migration. T cells also produce cytokines that are essential in psoriasis pathogenesis. The migration of T cells from circulation into dermis and from dermis into epidermis is the key checkpoints in psoriasis (9) . As reported in the product labeling, alefacept treatment resulted in a dose-dependent decrease in circulating total lymphocytes which predominantly affected the memory effector subset of the CD4+ and CD8+ T lymphocytes. In contrast to alefacept, efalizumab inhibits T lymphocyte activation without depleting memory effector T lymphocytes (59, 60) .
PART 2: PSORIASIS DISEASE-DRUG-DRUG INTERACTIONS
Disease conditions such as inflammation, infection, and cancer are associated with a down-regulation of drugmetabolizing enzymes and transporters (17, 61) . Psoriasis is a disease condition associated with elevated levels of proinflammatory cytokines (9-15). Overexpression of proinflammatory cytokines under disease condition is known to downregulate formation and suppress activities of drug-metabolizing enzymes including CYP enzymes. Although direct DDIs between therapeutic proteins and small molecules are unlikely, cytokines or cytokine modulators may indirectly modify the metabolism of small molecule drugs that are substrates for CYP enzymes through their effects on the regulation pathways of the CYP enzymes (16) (17) (18) . Figure 1 summarizes cytokines that are reported to have the potential to modify the formation, stability, and activity of CYP enzymes and are also involved in the pathogenesis of psoriasis. 
Cytokine Modulation as Pharmacodynamic Effects of Psoriasis Treatments
As discussed in Part 1, anti-cytokines and biologics targeting T cells in psoriasis therapy can have the pharmacodynamic effects of modulating expression levels of multiple cytokines either directly through therapeutic target inhibition or indirectly through improvement of disease condition. For example, the product labeling of TNFα inhibitors (adalimumab, infliximab, and etanercept) reported that they not only downregulate TNFα levels, but also reduce serum IL-6 level.
Whereas it has been consistently shown that TNFα and IL-6 levels were elevated in psoriasis patients and their expression levels were reduced following biological treatments, literature reports on other cytokines have been inconsistent. For example, IL-7 levels were increased in both the skin and serum of psoriasis patients; however, IL-7 levels did not show clear correlation with the disease severity, nor did they decrease with disease improvement after effective psoriasis treatment with anti-cytokine agents (11) . The cytokine alterations associated with psoriasis disease condition appear complex and with some degree of interconnectivity. For example, anti-TNFα therapy was shown to result in rapid decrease in IL-23 levels in psoriasis patients (62, 63) ; on the other hand, ustekinumab (an IL-12/23 inhibitor) improved histological psoriasis measures without affecting serum TNFα level (64) .
Recognizing data are available for only a limited number of cytokines, the above examples imply that the disease-DDI for psoriasis could be complicated for a given biologic product. Although these products typically are designed to target one or two specific cytokines, their pharmacodynamic effects could be associated with changes to a more complex cytokine network during treatment. Given the growing knowledge regarding the complexity of inflammatory conditions, the array of pipeline products aiming to treat psoriasis and other inflammatory diseases has expanded beyond those targeting cytokines known to be proinflammatory, e.g., TNFα and IL-6. Nonetheless, modulating inflammatory diseases by various mechanisms of action can be expected to lead to a common outcome of alleviating the inflammatory condition and reducing the levels of proinflammatory cytokines because of the involvement of proinflammatory cytokines in the disease condition. Hence, a holistic approach with in vivo studies is more appropriate for investigating the potential effects of psoriasis treatment on the exposure of CYP substrates or disease-DDI. Recently, the scientific community has devoted much attention to the development of in vitro models as a tool for evaluating disease-drug interaction. Such efforts are much needed to explore the potential for in vitro models to be an integral component of the strategy for evaluating disease-drug-drug interactions although the task may seem daunting.
Current Understanding of Disease-DDI in Rheumatoid Arthritis, an Inflammatory Disease Condition
Rheumatoid arthritis (RA) has been shown to downregulate CYP enzymes and to affect the exposure of small molecule drug simvastatin. Following the administration of simvastatin (a CYP3A4 substrate), RA patients had a higher exposure of both simvastatin and its active metabolite, β-hydroxy-simvastatin acid than healthy subjects (18) . Additionally, available data suggested that RA disease affected the simvastatin exposure to an extent approximately similar to the effect of coadministered verapamil (a CYP3A4 inhibitor) observed in healthy subjects. For instance, Jacobson et al. reported the mean AUC and Cmax values to be 135 ng*hr/mL and 31 ng/mL, respectively, for a 40 mg dose of simvastatin when coadministered with verapamil in healthy subjects, which were similar to the mean simvastatin AUC and Cmax values of 105 ng*hr/mL and 36 ng/mL, respectively, in RA patients (18, 65) . When administered alone at the same dose in healthy subjects, the simvastatin AUC and Cmax values were 32 ng*hr/mL and 6 ng/mL, respectively (65) . These PK data suggest that the RA disease condition may have been associated with a three-fold or greater increase of simvastatin exposure. A three-fold increase in exposure could be large enough to warrant dose adjustment in the case of drugs with narrow therapeutic window; therefore, consideration of the effect of inflammatory disease condition (or disease drug interaction) may be needed in some cases.
Schmitt et al. further evaluated RA disease-DDI using tocilizumab, an anti-IL6 receptor monoclonal antibody for RA indication, and simvastatin. A single intravenous infusion of tocilizumab in RA patients was shown to reduce simvastatin AUC by about 60% at 1 week after infusion (18) . In comparison, pretreatment with 600 mg rifampin (a CYP3A4 inducer) daily for 5 days resulted in a reduction of simvastatin AUC by 87% (66) . Available data reported by Schmitt et al. were obtained from a single intravenous dosing of tocilizumab, which could underestimate the maximum extent of interaction given tocilizumab is indicated for chronic treatment and the extent of cytokine modulation can be expected to increase with repeated dosing. However, the maximum extent of disease DDI for tocilizumab in RA patients remains to be defined experimentally.
Assessment of Potential IL-6-Mediated Disease-DDI in Psoriasis
Disease-drug interaction studies have not been conducted in subjects with psoriasis based on our literature review; therefore, the quantitative impacts of psoriasis disease condition on the expression and activity of CYP enzymes or on the PK of CYP substrate drugs are unknown. Similarly, disease-DDI for biological products has not been studied in subjects with psoriasis (67) . We believe that a quantitative understanding of the relative expression levels of proinflammatory cytokines between psoriasis patients and healthy subjects may offer insight into the potential for cytokine-mediated disease-drug interaction.
We chose to investigate IL-6 further for the following reasons: (a) IL-6 is considered a marker of the disease activity; (b) reduction of serum IL-6 level has been shown to be a ubiquitous PD response in psoriasis patients treated with biologics such as TNFα inhibitors, adalimumab, infliximab, and etanercept; and (c) the clinical outcome in psoriasis treatment has been shown to be associated with a time-and effect-size-dependent reduction of serum IL-6 level (68, 69) . Furthermore, given the available disease-DDI data in RA, comparative profiles of serum IL-6 levels in psoriasis patients versus RA patients may allow some understanding of the potential impact of the psoriasis disease condition on CYP enzymes via IL-6 modulation as well as the psoriasis disease-DDI potential related to IL-6 modulation.
We reviewed 11 individual reports that contained quantitative measurements of IL-6 levels in psoriasis patients and matched control healthy subjects. Data from these 11 studies were summarized in Table III . While a precise comparison of IL-6 concentrations across studies is not feasible without additional information such as sample handling and assay methodology, a high level impression can be derived. Overall, these studies showed that psoriasis patients had elevated systemic IL-6 levels and the IL-6 levels appeared to be comparable to those reported in RA patients. The mean or median systemic IL-6 concentrations in psoriasis patients ranged from 2.0 to 138.3 pg/mL which represented 1.3-to 12.1-fold of the IL-6 levels in matched control healthy subjects across studies. The average serum IL-6 level observed in RA patients reported by Schmitt et al. was 54 pg/mL (18) , which was in the range of the mean or median serum IL-6 concentrations in psoriasis patients. At individual subject level, the available data in psoriasis patients showed a wide IL-6 concentration range of 0-764 pg/mL.
It is noteworthy that the serum IL-6 concentrations showed high variability across the 11 studies possibly due to the differences in study locations, the study population, disease severities, analytical assays used for IL-6 measurements, and other factors. For instance, the psoriasis patients enrolled in the 11 studies had a wide range of the mean PASI scores (4.1 to 44.4) indicating a high variability in disease severities which may contribute to the observed variability in serum IL-6 levels. Furthermore, mean IL-6 levels increased with increasing disease severity according to two studies reported IL-6 data by disease severity, e.g., mild, moderate, and severe (70, 71) . Based on the IL-6 data, we propose that the potential for psoriasis disease-DDI exist and, therefore, upon initiation of biologics in psoriasis patients who are receiving concomitant CYP substrate with narrow therapeutic window, monitoring of the effect or drug concentration may be useful.
Utilizing the principle of in vitro-in vivo extrapolation, a physiologically-based pharmacokinetic (PBPK) model was recently established to describe the quantitative relationship between elevated levels of IL-6, hepatic CYP3A4 activity, and PK of simvastatin in RA patients (72) . According to the PBPK model-based simulations, the IL-6-mediated CYP3A activity regulation was negligible when the IL-6 concentrations were less than 10 pg/mL, while the CYP3A activity was significantly suppressed when the IL-6 concentrations were increased to above 50 pg/mL. If we were to use 10 and 50 pg/mL as the benchmarks, data in Table III would support that the IL-6-mediated disease-DDI in psoriasis could not be dismissed. However, inferences drawn from cross-study comparisons should be deemed as a call for Table III . Elevated Levels of Systemic IL-6 Expression in Subjects with Psoriasis. Serum or plasma IL-6 concentrations in psoriasis patients showed 1.3-to 12.1-fold of the levels in matched control healthy subjects across different studies. While intra-study comparison showed good correlation between PASI Scores and IL-6 expression levels, no significant correlation across different studies was observed due to the variability of the data. The variability of the data could be resulted from the differences in study population, analytical assays used for IL-6 measurements and other unknown factors The PASI values were reported as mean (and range) # The ratio was calculated as the mean or median value of the IL-6 level in psoriasis patients divided by the level in the matched control healthy subjects * The values were reported as median. n/a not available; PASI psoriasis area and severity index further investigation because a precise and quantitative comparison would require further understanding of the methodology used in determining IL-6 concentrations in various studies as well as in the source study(ies) supported the establishment of the PBPK database.
PART 3 STUDY DESIGN CONSIDERATIONS FOR PSORIASIS DISEASE-DDI CLINICAL TRIALS
Because the nature of disease-DDI involves the disease conditions (i.e., associated with elevated proinflammatory cytokines and suppressed CYP activity) and possibly the treatment responses (i.e., associated with normalization of cytokine levels and CYP activity), the study design considerations for clinical disease-DDI studies with biological products differ from those of conventional studies for DDI between two small molecule drug products. We highlight some particular considerations for clinical evaluations of psoriasis disease-DDI from the clinical pharmacology perspectives including study population, dosing regimen, and probe drugs.
Study Population
The indicated patient population would be an appropriate study population to assess the extent of disease-DDI and to inform clinical practice. For instance, adult subjects with moderate-to-severe plaque psoriasis could be the study population to investigate psoriasis disease-DDI with currently approved biological products. The investigation of disease-DDI requires the collection of the exposure data for CYP substrate drugs in the target population before and after biological therapies to determine whether the treatmentinduced disease improvement has an impact. Clinical studies are necessary because in vitro or animal studies have limited value in the qualitative and quantitative projection of clinical interactions, and the translation of results from in vitro to in vivo and from animal to human has been inconsistent (73) .
From a scientific perspective, healthy subjects would not be an appropriate population for investigating disease-DDI as they do not have the perturbed cytokines network reflective of the disease condition. Additionally, a subset of the indicated patients with the most severe condition would conceivably be the appropriate study population as they may have the greatest perturbation of cytokines and CYP suppression. As such, administration of biologic products may produce the greatest change in cytokine levels and the CYP activity in these subjects. Therefore, data from such a subset study may permit the assessment of the maximum extent of change in the exposure of CYP substrate upon treatment. An established relationship between the disease severity and the extent of cytokine elevation, and CYP suppression would lend further support to the use of a subset of target population.
Dosing Regimen
The recommended dosing regimen for an approved biological product would be appropriate for a psoriasis disease-DDI study. A study with a single dose of the biological product of interest can demonstrate that the treatment affects the exposure of victim drug (CYP substrate drug), i.e., the presence of disease-DDI as shown in the RA disease-DDI example where tocilizumab affected simvastatin exposure (18) . Because biological products typically have a long half-life, the CYP substrate drug can be administered at more than one time point after a single dose of biological product to evaluate the time-dependent potential of the disease-DDI. For instance, a single dose of tocilizumab reduced the exposure of simvastatin in a time-dependent manner (57% at 1 week and 39% at 5 weeks after tocilizumab administration) in RA patients, which could be due to a timedependent effect or concentration-dependent effect of tocilizumab on the reversal of CYP3A4 suppression (18) . While it was not evaluated in the above mentioned study, a greater reduction of simvastatin exposure can be expected following repeated dosing of tocilizumab because RA disease improvement may occur gradually and requires multiple dose treatment to show the full extent of disease-DDI.
The same principle would apply to psoriasis disease-DDI studies. As the psoriasis disease improvement progresses over time during a biological therapy, the magnitude of treatmentinduced modulation of cytokine expression levels and normalization of CYP enzyme activities are also likely to increase over time. Results from a study with a single dose of biological treatment may not be reflective of the extent of disease-DDI in patients receiving chronic treatment and eventually achieving the desired therapeutic effects at a pharmacodynamic steady state for the given treatment regimen. Therefore, a study with repeated doses of the biological product of interest at the approved dose regimen (dose and dosing frequency) would be more informative in defining the disease-DDI in clinical practice.
Probe Drugs
The utility of simvastatin as a probe substrate for CYP3A4 was demonstrated in the RA disease-DDI study (18) . However, multiple CYP substrate drugs (victim drugs) may need to be evaluated in psoriasis disease-DDI studies because of the complexity of the cytokine network involved in psoriasis disease condition and the treatment-induced improvements which may have impact on multiple CYP enzymes. The selection of appropriate CYP substrate drugs is important for the clinical investigation of disease-DDI. For the specific probe drug choices, we refer the readers to abundant literature resources for guidance (73, 74) . Given multiple CYP probe drugs of interest, the cocktail approach could be a reasonable strategy.
Other Considerations
Because psoriasis disease condition is associated with elevated levels of proinflammatory cytokines and the treatment effects of biological agents include the reduction of the levels of proinflammatory cytokines, it is possible that the extent of disease-DDI could be dependent on the extent of treatment effect (e.g., varying degrees of cytokine modulation and disease improvement) and may differ between responders and non-responders. As such, psoriasis disease-DDI evaluated in a clinical trial where clinical efficacy data could be obtained to distinguish responders from non-responders to the biological therapy may offer additional insight of disease-DDI. Inclusion of measurements of cytokine levels in addition to assessment of DDI and clinical efficacy would be very helpful to the data interpretation. Figure 2 shows examples of cytokine-mediated disease-DDI in inflammatory disease conditions (e.g., psoriasis) by illustrating schematic relationships among the expression levels of proinflammatory cytokines, the activity of drugmetabolizing enzyme CYP, and the PK exposure of CYP substrate.
Currently available biological therapies for psoriasis are not curative and their PD effects are reversible (75) . Return (relapse) or worsening (rebound) of the disease could occur when a therapy is discontinued or even during the treatment (76, 77) , which will require initiation of alternative therapies. Disease return or rebound could be associated with elevated cytokine expressions and CYP enzymes inhibition, possibly to a greater extent than the pretreatment state, resulting in increased exposure of small molecule drugs. The impact of disease relapse or rebound on exposure of CYP substrates is a special case where disease-DDI investigation could be relevant scientifically and clinically. To evaluate the effects of disease relapse or rebound, it is more practical to conduct a study in a cohort of subjects meeting the disease relapse/ rebound criteria, as opposed to building it into Phase 3 trials. Insights regarding the necessity of such a targeted study could be gained by obtaining PD data and biomarker information such as cytokine level changes in patients with disease relapse or rebound in a larger trial setting (such as Phase 3 trials).
PART 4: CONCLUSIONS AND PERSPECTIVES
The introduction of targeted biologic therapies has greatly improved the treatment options for psoriasis although the pathogenesis of the autoimmune skin disease has not been fully elucidated. The potential for psoriasis disease-DDI is implicit because altered expressions of cutaneous and systemic cytokines are well demonstrated in psoriasis patients. In particular, the elevated proinflammatory cytokines in psoriasis patients can suppress CYP enzymes and the disease improvement can be associated with a reversal of CYP enzyme suppression resulting in disease-DDI. The potential consequences of disease-DDI include a reduction of systemic exposure and thus reduced efficacy of drugs that are substrates of impacted CYP enzymes.
A simple psoriasis disease-drug interaction study (to evaluate the disease impact on PK of CYP substrate drugs) would pave the way for addressing the more complicated psoriasis disease-DDI when biological therapies are involved. Psoriasis disease-DDI investigation may not be necessary if the extents to which the psoriasis disease condition affects the exposures of CYP substrate drugs are found not clinically meaningful. In other words, if the inflammatory disease condition, psoriasis, does not suppress the CYP enzymes to a clinically meaningful extent, an improvement on psoriasis condition after treatment with a biologic agent would not be expected to significantly alter the exposures of CYP substrates. On the other hand, if psoriasis disease condition has a clinically meaningful impact on the exposure of CYP substrate drugs, further investigation of disease-DDI would be important for biologics in psoriasis treatment.
Findings from our literature review revealed that psoriasis patients had elevated systemic IL-6 levels compared to the matched healthy control subjects and suggested the IL-6-mediated disease-DDI in psoriasis patients may not be dismissed. In addition to IL-6, other proinflammatory cytokines can be elevated and also contribute to the disease-DDI in psoriasis; therefore, a holistic approach of disease-DDI evaluation carried out in vivo in psoriasis patients would be more Fig. 2 . Cytokine-mediated disease-DDI in inflammatory disease conditions (e.g., psoriasis). Proinflammatory cytokines are overexpressed under an inflammatory disease condition such as psoriasis. Elevated levels of cytokines down-regulate the formation, stability, and activity of drug-metabolizing enzymes including cytochrome P450 enzymes (CYP), which in turn result in increased exposure of CYP substrate. Following biological treatment and disease condition improvement, the exposure of the CYP substrate is normalized to that in healthy subjects (assuming that maximal treatment effect induces complete normalization of cytokine levels into healthy state). In the event of disease return (relapse) or worsening (rebound) when the biological therapy is discontinued or even during the treatment, reelevated levels of cytokines result in CYP enzymes inhibition and increased exposure of small molecule drugs. In the event of the disease rebound, the exposure of the CYP substrate could be even higher than that before the initiation of the biological treatment due to worsening of the disease (see text). In situations of disease relapse or rebound, and when new therapies are reinitiated, patients who are receiving concomitant CYP substrate, monitoring of the effect or drug concentration is needed, particularly for CYP substrates with narrow therapeutic index where the dose is individually adjusted appropriate. Efforts in developing in vitro models may someday produce useful tools to be integrated into the disease-DDI evaluation strategy. One publication has shown PBPK modeling approach to be successful in describing the impact of IL-6 on CYP activity, suggesting that modeling approach may be useful in integrating data to describe complex cytokine-driven CYP enzyme modulations. Data on more cytokine biomarkers relevant to disease conditions of interest are needed to enrich the knowledgebase and facilitate further development of advanced computational approach for in silico prediction of the disease-DDI potential for new biological therapeutics.
